The best indicator for Bristol Myers Squibb (BMY)
We backtested 20 indicators across daily, weekly and hourly charts on real Bristol Myers Squibb (BMY) history. Here's what actually worked — risk-adjusted, out-of-sample, with costs.
EMA 50/200 Cross
On the daily chart, this is the strongest risk-adjusted edge we found for Bristol Myers Squibb (BMY) over ~54.0 years — trailing buy-and-hold by 1.8% CAGR.
The winner on each chart
Every indicator, ranked
Ranked by Sharpe (risk-adjusted return). Hypothetical, fees included.
| # | Indicator | TF | CAGR | Sharpe | Max DD | Win | Trades | vs B&H |
|---|---|---|---|---|---|---|---|---|
| 1 | EMA 50/200 Cross ✓ | Daily | 8.6% | 0.51 | -62.0% | 36.7% | 30 | -1.8% |
| 2 | EMA 20/50 Cross ✓ | Weekly | 8.2% | 0.51 | -62.5% | 47.6% | 21 | -2.1% |
| 3 | Stochastic ✓ | Daily | 6.0% | 0.44 | -51.2% | 70.9% | 265 | -4.3% |
| 4 | WaveTrend (8/6/4) ✓ | Daily | 6.4% | 0.43 | -46.2% | 68.7% | 198 | -3.9% |
| 5 | Williams %R ✓ | Weekly | 5.3% | 0.43 | -62.9% | 76.5% | 68 | -4.9% |
| 6 | SMA 50/200 Cross ✓ | Daily | 6.4% | 0.41 | -50.2% | 43.9% | 41 | -3.9% |
| 7 | Williams %R | Daily | 4.9% | 0.36 | -54.6% | 65.4% | 347 | -5.5% |
| 8 | CCI ✓ | Daily | 4.8% | 0.36 | -50.2% | 66.8% | 262 | -5.5% |
| 9 | ADX / DMI ✓ | Weekly | 4.2% | 0.35 | -51.8% | 47.3% | 74 | -6.1% |
| 10 | Bollinger Mean-Reversion | Daily | 3.5% | 0.31 | -45.9% | 71.6% | 211 | -6.8% |
| 11 | Money Flow Index ✓ | Weekly | 4.8% | 0.42 | -42.9% | 100.0% | 11 | -5.5% |
| 12 | Money Flow Index ✓ | Daily | 3.8% | 0.3 | -58.9% | 71.4% | 49 | -6.5% |
| 13 | Bollinger Mean-Reversion ✓ | Weekly | 3.0% | 0.3 | -49.5% | 77.8% | 36 | -7.3% |
| 14 | Stochastic ✓ | Weekly | 3.3% | 0.3 | -58.9% | 77.8% | 45 | -7.0% |
✓ = held up out-of-sample. Hypothetical, costs included. See methodology.
For Bristol Myers Squibb (BMY), EMA 50/200 Cross on the daily timeframe gave the best balance of return and risk in our test. It still trailed buy-and-hold on raw return — but remember: this is a hypothetical backtest of a standard rule, not a recommendation. Markets change. See the methodology and disclaimer.
More stock
Get the weekly edge report
The best-performing indicator per asset, what changed this week, and the honest caveats — straight to your inbox.